Prof. Linghua Li | Cancer Science | Best Researcher Award

Prof. Linghua Li | Cancer Science | Best Researcher Award

Guangzhou Eighth People’s Hospital | China

Author Profile

ORCID ID

๐ŸŒŸLinghua Li, Ph.D., M.S., B.S. ๐ŸŒ

Head Director, Infectious Disease Center
Guangzhou Eighth Peopleโ€™s Hospital, Guangzhou Medical University

๐Ÿ‘ฉโ€โš•๏ธBiography

Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.

Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.

As the Head Director of the Infectious Disease Center at Guangzhou Eighth Peopleโ€™s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:

  • National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
  • Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
  • NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.

In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:

  • ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.

Dr. Liโ€™s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.

๐ŸงฌKey Areas of Expertise

๐Ÿ”ฌ HIV Prevention and Treatment
๐ŸŒฟ Opportunistic Infections
๐Ÿ“Š Clinical Trials and Data Analysis
๐Ÿง‘โ€โš•๏ธ Internal and Infectious Diseases

๐Ÿ“šAcademic Background

  • B.S., Clinical Medicine, Medical School of Peking University (1997)
  • M.S., Internal Medicine, Sun Yat-sen University (2008)
  • Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
  • Visiting Scholar, UNC-Chapel Hill (2012)
  • Visiting Scholar, Duke University (2014)

๐Ÿ”ฌResearch Impact

๐ŸŒŸ Over 20 funded research projects
๐Ÿ“„ Numerous publications in infectious disease and public health journals
๐Ÿ“š Active contributor to advancing HIV prevention strategies in China

Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. ๐ŸŒโœจ

โœจ Conclusion

Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. ๐ŸŒŸ๐ŸŒ

๐Ÿ“Š๐Ÿ”ฌNOTABLE PUBLICATION:
  • Utilizing Proteinโ€“Peptide Hybrid Microarray for Time-Resolved Diagnosis and Prognosis of COVID-19
    • Authors: Peiyan Zheng, Baolin Liao, Jiao Yang, Hu Cheng, Zhangkai Cheng, Huimin Huang, Wenting Luo, Yiyue Sun, Qiang Zhu, Yi Deng, et al.
    • Journal: Microorganisms
    • Year: 2023

Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Zhejiang Chinese Medical University | China

Author Profile

Scopus

Biography of Hong-Hong Zhu, MD, MSc, PhD โ€“ Professor of Extraordinary Ability ๐ŸŽ“๐ŸŒ

๐ŸŽฏ Current Role: Leader in Medical Research

Dr. Hong-Hong Zhu is the Head of the Center for Medical Research at Zhejiang Chinese Medical University Affiliated Four-Province-Bordering Hospital of Traditional Chinese Medicine (Quzhou Hospital of TCM). Her leadership in medical research spans over three decades.

๐Ÿ“œ Educational Background

  • Ph.D. in Epidemiology from Johns Hopkins University (JHU) Bloomberg School of Public Health (2007)
  • Postdoctoral Training at the U.S. National Institutes of Health (NIH)
  • MD & Masterโ€™s Degree in Medicine from Zhejiang University
  • M.Sc. from Clemson University

๐Ÿ’ก Key Contributions: Breast Cancer Etiology Pioneer

Dr. Zhu was the first to propose the Synergistic Interaction Theory for breast cancer, linking environmental carcinogens and exogenous hormone use. Her work has significantly advanced the understanding of cancer causes.

๐Ÿ”ฌ Innovator in Colorectal Cancer Prevention

With 32 years of research in colorectal cancer prevention, Dr. Zhu and her team developed cost-effective screening methods that have saved millions of lives worldwide.

๐Ÿ† Academic Achievements and Awards

  • 135 Publications in esteemed journals
  • 35 Awards, including:
    • Best Poster Award (NIH) for breast cancer research (2006)
    • Delta Omega Honor from the U.S. National Public Health Honor Society (2007)
    • Second Place in Scientific Competition in Epidemiology and Public Health (2007)
    • Professor of Extraordinary Ability (2015)
    • Sigma Xi Scientific Research Honor (2024)

๐Ÿ“š Editor and Peer Reviewer

  • Editor-in-Chief of the Journal of GHR (since 2015)
  • Peer Reviewer for academic journals for over 20 years
  • Grant Reviewer for the U.S. Department of Health and Human Services (12 years)

Dr. Hong-Hong Zhu’s contributions to medical research have made her a global figure in epidemiology and cancer prevention.

๐Ÿ” Conclusion

With over three decades of research in epidemiology and disease prevention, Dr. Hong-Hong Zhu has made groundbreaking contributions in breast and colorectal cancer research. Her innovative approaches to cancer screening and prevention have been life-saving on a global scale. She remains a recognized leader in public health, continuing to inspire through her research, publications, and numerous honors. ๐ŸŒŸ

 

๐Ÿ“Š๐Ÿ”ฌNOTABLE PUBLICATION:

 

  • Combining FITs and HRFQ with colonoscopy improve the cost-effectiveness of a 9-year mass colorectal cancer screening program
    Authors: Cai, S.-R., Huang, Y.-Q., Li, Q.-R., Yang, J.-H., Zheng, S.
    Journal: ESMO Open
    Year: 2024

 

  • Sex difference in alcohol consumption associated with colorectal cancer risk in Quzhou, China: A nested case-control study
    Authors: Lai, S.-M., Zhu, H.-H., Gan, Z.-J., Wang, Z.-C., Liao, X.-F.
    Journal: Preventive Medicine Reports
    Year: 2024

 

  • Antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged from 50 to 102 years
    Authors: Zhu, H.-H., Sun, G.-Q., Wu, J.-Y., Wang, Z.-C., Liao, X.-F.
    Journal: Frontiers in Immunology
    Year: 2023